Safety of Ferumoxytol in Patients With Anemia and CKD

American Journal of Kidney Diseases

Volumn 52, Issue 5, 2008, Pages 907-915

  Singh, Ajay ^a,b   Patel, Tejas ^a,b   Hertel, Joachim ^c   Bernardo, Marializa ^d   Kausz, Annamaria ^e,f   Brenner, Louis ^a,b,e  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c University Hospital Augusta   (United States)

^d Southwest Houston Research   (United States)

^e AMAG PHARMACEUTICALS INC   (United States)

^f TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Anemia; chronic kidney disease; end stage renal disease; ferumoxytol; intravenous iron; iron deficiency; iron deficiency anemia

Indexed keywords

FERUMOXYTOL; PLACEBO;

ADULT; AGED; ANEMIA; ARTICLE; BACTEREMIA; CELLULITIS; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DIZZINESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG WITHDRAWAL; DYSGEUSIA; ENDOCARDITIS; FATIGUE; FEMALE; FOLLOW UP; GANGRENE; HEADACHE; HEMODYNAMICS; HOT FLUSH; HUMAN; HYPERTENSION; HYPOTENSION; INJECTION SITE BLEEDING; INJECTION SITE CONTUSION; INJECTION SITE ERYTHEMA; INJECTION SITE IRRITATION; INJECTION SITE PAIN; INJECTION SITE SWELLING; INJECTION SITE WARMTH; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MULTICENTER STUDY; NAUSEA; OSTEOMYELITIS; PATIENT COMPLIANCE; PHASE 3 CLINICAL TRIAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; SEPSIS; SINGLE DRUG DOSE; STAPHYLOCOCCUS INFECTION; URINARY TRACT INFECTION; VITAL SIGN; VOMITING;

AGED; ANEMIA, IRON-DEFICIENCY; CHRONIC DISEASE; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; FERROSOFERRIC OXIDE; HUMANS; KIDNEY DISEASES; MALE; MIDDLE AGED;

EID: 54149119169     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ajkd.2008.08.001     Document Type: Article

References (40)

1. Astor B.C., Muntner P., Levin A., Eustace J.A., and Coresh J. Association of kidney function with anemia: The Third National Health and Nutrition Examination Survey (1988-1994). Arch Intern Med 162 (2002) 1401-1408
2. Kazmi W.H., Kausz A.T., Khan S., et al. Anemia: An early complication of chronic renal insufficiency. Am J Kidney Dis 38 (2001) 803-812
3. Eschbach J.W. The anemia of chronic renal failure: Pathophysiology and the effects of recombinant erythropoietin. Kidney Int 35 (1989) 134-148
4. Fishbane S., and Maesaka J.K. Iron management in end-stage renal disease. Am J Kidney Dis 29 (1997) 319-333
5. Silverberg D.S., Blum M., Agbaria Z., et al. Intravenous iron for the treatment of predialysis anemia. Kidney Int Suppl 69 (1999) S79-S85
6. Spinowitz B.S., Kausz A.T., Baptista J., et al. Ferumoxytol for treating iron deficiency anemia in CKD. J Am Soc Nephrol 19 (2008) 1599-1605
7. Coyne D.W., Kapoian T., Suki W., et al. Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: Results of the Dialysis Patients' Response to IV Iron with Elevated Ferritin (DRIVE) Study. J Am Soc Nephrol 18 (2007) 975-984
8. Macdougall I.C., Tucker B., Thompson J., Tomson C.R., Baker L.R., and Raine A.E. A randomized controlled study of iron supplementation in patients treated with erythropoietin. Kidney Int 50 (1996) 1694-1699
9. Van Wyck D.B., Roppolo M., Martinez C.O., Mazey R.M., and McMurray S. A randomized, controlled trial comparing IV iron sucrose to oral iron in anemic patients with nondialysis-dependent CKD. Kidney Int 68 (2005) 2846-2856
10. National Kidney Foundation. Using iron agents, in KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease. Am J Kidney Dis 47 suppl 3 (2006) S58-S70
11. American Regent Laboratories Inc. Dexferrum® [package insert] (2001), American Regent Laboratories Inc, Shirley, NY
12. Watson Pharma Inc. INFeD® Prescribing Information (2001), Watson Pharma Inc, Morristown, NJ
13. Watson Pharma Inc. Ferrlecit® [package insert] (2006), Watson Pharma Inc, Corona, CA
14. American Regent Inc. Venofer® [package insert] (2005), American Regent Inc, Shirley, NY
15. Fishbane S., Ungureanu V.D., Maesaka J.K., Kaupke C.J., Lim V., and Wish J. The safety of intravenous iron dextran in hemodialysis patients. Am J Kidney Dis 28 (1996) 529-534
16. Bailie G.R., Clark J.A., Lane C.E., and Lane P.L. Hypersensitivity reactions and deaths associated with intravenous iron preparations. Nephrol Dial Transplant 20 (2005) 1443-1449
17. Faich G., and Strobos J. Sodium ferric gluconate complex in sucrose: Safer intravenous iron therapy than iron dextrans. Am J Kidney Dis 33 (1999) 464-470
18. Van Wyck D.B., Cavallo G., Spinowitz B.S., et al. Safety and efficacy of iron sucrose in patients sensitive to iron dextran: North American clinical trial. Am J Kidney Dis 36 (2000) 88-97
19. Auerbach M., and Al Talib K. Low-molecular weight iron dextran and iron sucrose have similar comparative safety profiles in chronic kidney disease. Kidney Int 73 (2008) 528-530
20. Chertow G.M., Mason P.D., Vaage-Nilsen O., and Ahlmen J. On the relative safety of parenteral iron formulations. Nephrol Dial Transplant 19 (2004) 1571-1575
21. Prakash S., Walele A., Dimkovic N., Bargman J., Vas S., and Oreopoulos D. Experience with a large dose (500 mg) of intravenous iron dextran and iron saccharate in peritoneal dialysis patients. Perit Dial Int 21 (2001) 290-295
22. Macdougall I.C., and Roche A. Administration of intravenous iron sucrose as a 2-minute push to CKD patients: A prospective evaluation of 2,297 injections. Am J Kidney Dis 46 (2005) 283-289
23. Landry R., Jacobs P.M., Davis R., Shenouda M., and Bolton W.K. Pharmacokinetic study of ferumoxytol: A new iron replacement therapy in normal subjects and hemodialysis patients. Am J Nephrol 25 (2005) 400-410
24. Spinowitz B.S., Schwenk M.H., Jacobs P.M., et al. The safety and efficacy of ferumoxytol therapy in anemic chronic kidney disease patients. Kidney Int 68 (2005) 1801-1807
25. Spinowitz B., Besarab A., Bolton W.K., et al. Ferumoxytol as intravenous iron replacement therapy in chronic kidney disease (CKD) patients not on dialysis: Evaluation of safety and efficacy in two phase III Studies. J Am Soc Nephrol 17 (2006) 342A (abstr)
26. Hedin H., and Ljungstrom K.G. Prevention of dextran anaphylaxis. Ten years experience with hapten dextran. Int Arch Allergy Immunol 113 (1997) 358-359
27. Agarwal R., Rizkala A.R., Bastani B., Kaskas M.O., Leehey D.J., and Besarab A. A randomized controlled trial of oral versus intravenous iron in chronic kidney disease. Am J Nephrol 26 (2006) 445-454
28. Chandler G., Harchowal J., and Macdougall I.C. Intravenous iron sucrose: Establishing a safe dose. Am J Kidney Dis 38 (2001) 988-991
29. Michael B., Coyne D.W., Fishbane S., et al. Sodium ferric gluconate complex in hemodialysis patients: Adverse reactions compared to placebo and iron dextran. Kidney Int 61 (2002) 1830-1839
30. St Peter W.L., Lambrecht L.J., and Macres M. Randomized cross-over study of adverse reactions and cost implications of intravenous push compared with infusion of iron dextran in hemodialysis patients. Am J Kidney Dis 28 (1996) 523-528
31. Van Wyck D., Anderson J., and Johnson K. Labile iron in parenteral iron formulations: A quantitative and comparative study. Nephrol Dial Transplant 19 (2004) 561-565
32. Jacobs P., Lewis J., and Frigo T. Bleomycin detectable iron and percent transferrin saturation in the serum of patients receiving either ferumoxytol, iron gluconate or iron sucrose. J Am Soc Nephrol 15 (2004) 546A (abstr)
33. Lewis J., Jacobs P., and Frigio T. Comparison of free iron in ferumoxytol with other iron therapeutics. J Am Soc Nephrol 14 (2003) 771A (abstr)
34. Saadeh C.E., and Srkalovic G. Acute hypersensitivity reaction to ferric gluconate in a premedicated patient. Ann Pharmacother 39 (2005) 2124-2127
35. Zager R.A., Johnson A.C., and Hanson S.Y. Parenteral iron therapy exacerbates experimental sepsis. Kidney Int 65 (2004) 2108-2112
36. Fishbane S. Review of issues relating to iron and infection. Am J Kidney Dis 34 suppl 2 (1999) S47-S52
37. Bullen J.J., Rogers H.J., Spalding P.B., and Ward C.G. Natural resistance, iron and infection: A challenge for clinical medicine. J Med Microbiol 55 (2006) 251-258
38. Auerbach M., and Rodgers G.M. Intravenous iron. N Engl J Med 357 (2007) 93-94
39. Charytan C., Qunibi W., and Bailie G.R. Comparison of intravenous iron sucrose to oral iron in the treatment of anemic patients with chronic kidney disease not on dialysis. Nephron Clin Pract 100 (2005) c55-c62
40. Chertow G.M., Mason P.D., Vaage-Nilsen O., and Ahlmen J. Update on adverse drug events associated with parenteral iron. Nephrol Dial Transplant 21 (2006) 378-382